Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.52 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29373829 | 0.84 | KMT2A (1.00) | KMT2ACES2CES1L3MBTL1LMNA | |
| SCHEMBL398165 | 0.84 | KMT2A (1.00) | KMT2ACES2CES1L3MBTL1LMNA | |
| SCHEMBL28015961 | 0.82 | KMT2A (0.96) | KMT2ACES2CES1L3MBTL1LMNA | |
| SCHEMBL28005707 | 0.82 | KMT2A (0.96) | KMT2ACES2CES1L3MBTL1LMNA | |
| Water SCHEMBL6228901 | 0.82 | KMT2A (0.72) | KMT2ACES2CES1L3MBTL1LMNA | |
| SCHEMBL16460100 | 0.81 | KMT2A (0.78) | KMT2ACES2CES1L3MBTL1LMNA | |
| SCHEMBL31135050 | 0.81 | KMT2A (0.78) | KMT2ACES2CES1L3MBTL1LMNA | |
| SCHEMBL2419875 | 0.81 | KMT2A (0.66) | KMT2ACES2CES1L3MBTL1LMNA | |
| SCHEMBL31369148 | 0.80 | KMT2A (0.75) | KMT2ACES2CES1L3MBTL1LMNA | |
| SCHEMBL87791 | 0.80 | KMT2A (0.75) | KMT2ACES2CES1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100494182-C | Regulatory factor of tumor necrosis alpha factor | GENZYME CORP (US) | 2009-06-03 | — | — | CN | claimed |
| CN-1441787-A | Modulators of TNF-alpha signaling | GENZYME CORP (US) | 2003-09-10 | — | — | CN | claimed |
| US-8765791-B2 | Method of treating cancer using a neuropeptide Y 5R (NP Y5R) antagonist | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| US-20110112102-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | UNIVERSITY HEALTH NETWORK | 2011-05-12 | — | — | US | disclosed |
| EP-2262499-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | University Health Network (CA) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009111868-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | UNIVERSITY HEALTH NETWORK (CA) | 2009-09-17 | — | — | WO | disclosed |
| EP-1635813-A4 | COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA | MERCK & CO INC (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20080064632-A1 | Combination Therapy for the Treatment of Obesity | MERCK SHARP & DOHME CORP. | 2008-03-13 | — | — | US | disclosed |
| EP-1483266-B1 | SPIRO COMPOUNDS WITH NPY ANTAGONISTIC ACTIVITY | BANYU PHARMA CO LTD (JP) | 2008-02-27 | — | — | EP | disclosed |
| EP-1534074-A4 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | MERCK & CO INC (US) | 2008-01-09 | — | — | EP | disclosed |
| US-7304072-B2 | E.g.,cis-N-(4-benzoylphenyl)-4-hydroxy-3'-oxospiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxamide; useful as neuropeptide Y receptor antagonists and as agents for therapy of cardiovascular disorders, central nervous system disorders, metabolic diseases, respiratory and urogenital disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-12-04 | — | — | US | disclosed |
| US-6388077-B1 | CARDIOVASCULAR DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-14 | — | — | US | disclosed |
| US-20020052371-A1 | NOVEL SPIRO COMPOUNDS | MSD K.K. (JP) | 2002-05-02 | — | — | US | disclosed |
| US-6335345-B1 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS; OBESITY AND BULIMIA TREATMENT; CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL, METABOLIC AND EATING DISORDERS; ANTIDIABETIC AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-01-01 | — | — | US | disclosed |
| US-6326375-B1 | CONTAINING AN UREA GROUP | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-12-04 | — | — | US | disclosed |
| WO-2001014376-A1 | NOVEL SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-03-01 | — | — | WO | disclosed |
| EP-0641302-B1 | ALCOHOLS AS POTASSIUM CHANNEL OPENERS AND IN TREATMENT OF URINARY INCONTINENCE | ZENECA LTD (GB) | 1997-12-10 | — | — | EP | disclosed |
| US-5411973-A | Potassium channel openers, urinary incontinence | ZENECA LIMITED (GB) | 1995-05-02 | — | — | US | disclosed |
| EP-0641302-A1 | ALCOHOLS AS POTASSIUM CHANNEL OPENERS AND IN TREATMENT OF URINARY INCONTINENCE | ZENECA LIMITED (GB) | 1995-03-08 | — | — | EP | disclosed |
| WO-1993023358-A1 | ALCOHOLS AS POTASSIUM CHANNEL OPENERS AND IN TREATMENT OF URINARY INCONTINENCE | ZENECA LIMITED (GB) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064632-A1 | Combination Therapy for the Treatment of Obesity | NPY4R, GPR119, GIPR | KMT2A 2299/4885CES2 2773/4885CES1 1419/4885 |
| US-20020052371-A1 | NOVEL SPIRO COMPOUNDS | GPR119, NPY1R, OPRK1 | KMT2A 3160/4885CES2 2659/4885CES1 1368/4885 |
| US-20110112102-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | NPY5R, NPY1R, SSTR5 | KMT2A 1343/4885CES2 4654/4885CES1 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.